SCHEMBL4644482

SCHEMBL4644482

C=CCCOc1cccc(OCc2ccccc2)c1C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
BRD4 O60885 1/20 0.48
FOLH1 Q04609 1/20 0.47
HTR1A P08908 2/20 0.45
ADRA1D P25100 2/20 0.45
ADRA1A P35348 2/20 0.45
ADRA1B P35368 2/20 0.45
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
RAB9A P51151 1/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 3/20 0.44
MAPK1 P28482 1/20 0.43
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4643769 0.88 FOLH1 (0.56) KDM4EBRD4FOLH1HTR1AADRA1D
SCHEMBL4643985 0.85 KDM4E (0.50) KDM4EBRD4FOLH1HTR1AADRA1D
SCHEMBL629367 0.84 KDM4E (0.47) KDM4EBRD4FOLH1MAPTL3MBTL1
SCHEMBL29060132 0.82 FOLH1 (0.50) KDM4EBRD4FOLH1LMNAMAPT
SCHEMBL4645964 0.82 CA12 (0.56) KDM4E
SCHEMBL2888832 0.81 TDP1 (0.46) KDM4EBRD4FOLH1HTR1AADRA1D
SCHEMBL9724299 0.79 HPGD (0.56) KDM4EBRD4FOLH1LMNAMAPT
SCHEMBL20802709 0.79 KDM4E (0.47) KDM4ELMNAMAPTL3MBTL1RAB9A
SCHEMBL1097551 0.79 SGMS2 (0.54) KDM4EBRD4FOLH1LMNAMAPT
SCHEMBL5120937 0.79 CA12 (0.59) KDM4EBRD4FOLH1HTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1960377-A1 l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS Novartis AG (CH) 2008-08-27 EP disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors PTPRS, IRS1, PTPMT1 KDM4E 3278/4885BRD4 3536/4885FOLH1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.